language_icon
EN
HI

Gland Pharma Share price

GLAND

1618

8.60 (-0.53%)
NSE
BSE
Last updated on 16 Mar, 2026 | 15:29 IST
Today's High

1620.00

Today's Low

1573.60

52 Week Low

1277.80

52 Week High

2131.00

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Gland Pharma Chart

Gland Pharma Share Key Metrics

Volume
57508.00
Market Cap
26799.28 CR
LTQ@LTP
15@1618.00
ATP
1598
Var Margin
14.89 %
Circuit Range
1301.3-1951.9
Delivery %
64.13 %
Value
9.19 CR
ASM/GSM
No
Market Lot
1

Summary

16 Mar, 2026 | 15:29 को, Gland Pharma का शेयर प्राइस आज ₹1618 पर है, जो दिन के लिए 8.60% की -0.53 दर्शाता है। स्टॉक की इंट्राडे मूवमेंट ₹1573.60 और ₹1620.00 के बीच रही है, जबकि 52‑सप्ताह के आधार पर यह ₹1277.80 से ₹2131.00 तक रही है। ट्रेडिंग गतिविधि के मामले में, Gland Pharma ने 57508 शेयरों का वॉल्यूम रिकॉर्ड किया है, जिसका मार्केट कैपिटलाइज़ेशन ₹164756423 है। स्टॉक की एवरेज ट्रेडेड प्राइस ₹159800 है, जबकि लास्ट ट्रेडेड क्वांटिटी एट लास्ट ट्रेडेड प्राइस (LTQ@LTP) 15,161800 रही। यह स्टॉक ₹1301.3-1951.9 की सर्किट रेंज में ट्रेड करता है, और आज का कारोबार मूल्य ₹9.19 CR है। दिन के लिए डिलीवरी परसेंटेज 64.13% रही। इसके अतिरिक्त, Gland Pharma वर्तमान में No फ्रेमवर्क के तहत आता है और 1 के मार्केट लॉट साइज़ में ट्रेड करता

Gland Pharma Fundamentals

View More
P/E Ratio

31.66

P/B Ratio

2.73

Div. Yield

1.11

Sector P/E

59.54

Sector P/B

2.65

Sec. Div. Yield

0.59

Gland Pharma Resistance and Support

Pivot 1628.4

Resistance

First Resistance

1655.1

Second Resistance

1683.6

Third Resistance

1710.3

Support

First Support

1599.9

Second Support

1573.2

Third Support

1544.7

Gland Pharma Futures & Options

Data Not Found

Gland Pharma Shareholding Pattern

View More
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
Total Promoters
Segment
Percent

Total Promoters

51.83%

Mutual Fund

31.42%

Insurance

1.33%

Foreign Institutional Investors

7.58%

Domestic Institutional Investors

0.23%

Retail

7.61%

Others

0%

Total Promoters
MAR '25
51.83%
JUN '25
51.83%
SEP '25
51.83%
DEC '25
51.83%

Gland Pharma Corporate Actions

DateAgenda
2026-01-28Quarterly Results

Gland Pharma News

No Data Found

About Gland Pharma AboutThe

NSE : 1186  
BSE : 543245  
ISIN : INE068V01023  

The Company was incorporated as ‘Gland Pharma Private Limited’ a private limited company under the Companies Act 1956 on March 20 1978 and was granted the certificate of incorporation by Registrar of Companies Andhra Pradesh at Hyderabad. Subsequently the name of the Company was changed to ‘Gland Pharma Limited’ pursuant to a special resolution passed by the shareholders of the Company on December 5 1994 and a fresh certificate of incorporation dated April 25 1995 was issued by the Registrar of Companies Andhra Pradesh at Hyderabad consequent upon change of name and conversion into a public limited company under the Companies Act 1956.Major events and milestones of the Company :2019- Filed Dexrazoxane for Injection the first filing with the National Medical Products Administration China and received clinical waiver2018- Received ANDA approval for Enoxaparin Sodium Injection USP for the US market- Received ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP 0.1% the first Ophthalmic product approval2017- Fosun Singapore acquired 74% stake in the Company2016- Obtained USFDA approval for the facilities at Jawaharlal Nehru Pharma City Visakhapatnam- Obtained USFDA approval for the manufacturing facility at Pashamylaram- Obtained USFDA approval for the facility at the Visakhapatnam Special Economic Zone2014- Obtained USFDA approval for small volume parenteral manufacturing facility at Visakhapatnam- Commissioned the Pashamylaram Unit-II manufacturing facility- Received the ‘Certificate of GMP Compliance of a Manufacturer’ from MHRA (UK) for manufacturing facility at Dundigal- Capital infusion of US$ 100 million into the Company pursuant to private equity investment aggregating to approximately US$ 200 million with KKR Floorline Investment Pte Ltd2012- Received the ‘Certificate of GMP Compliance of a Manufacturer’ from BGV Hamburg (Germany) for the manufacturing facility at Dundigal2010- Launched Heparin Sodium Injection in the US2007- Capital infusion of approximately Rs.1000 million into the Company pursuant to private equity investment aggregating to approximately Rs.1200 million with EILSF Co-Invest I LLC2004 - 2005- Launch of Enoxaparin Sodium Injection (Cutenox) in India and Rest of the world markets2003- Received USFDA approval for the manufacturing facility at Dundigal2000- Set up the in-house R&D facility at Dundigal Hyderabad1978- Incorporation of the Company by P.V.N. RajuAwards accreditations and recognitions received by the Company :2019- The Company was awarded the “Best Exporter” by the Hyderabad Customs- The Company was awarded the “Express Pharma Excellence Awards 2019” under the turnover base Rs. 500 – 2000 crore category organized by the Express Pharma and Optel Group- The Company was awarded the “Telangana Best Employer Brand Award” at the 14th Employer Branding Awards organised by the Employer Branding Institute India2018- The Company was awarded the “Top Exporter” by the Hyderabad Customs Customs and Central Excise Government of India- The Company was awarded the “Outstanding Export Performance Award” under Formulations Silver Star category by Pharmaceuticals Export Promotion Council of India2017- The Company was awarded the “Excellence in Export Performance” at the Federation of Telangana and Andhra Pradesh Chambers of Commerce and Industry instituted by Surana Group of Industries Secunderabad- The Company was awarded the “Outstanding Export Performance Award” under Formulations Fast Growing -1 category by Pharmaceuticals Export Promotion Council of India2016- The Company was awarded the “Top Exporter/Importer” by the Hyderabad Customs Commissionerate Customs and Central Excise Government of India2014- The Company was awarded the “Outstanding Exports Performance Award” under the Regional (America and Oceania) category by Pharmaceuticals Export Promotion Council of India- The Company received the BS OHSAS 18001:2007 certifying the occupational health and safety management system of the manufacturing facility at Dundigal- The Company received ISO 14001:2015 certifying the environmental management system of the manufacturing facility at Dundigal- The Company received ISO 9001:2015 certifying the quality management system of manufacturing facility at Dundigal

Read More

Gland Pharma Management

NamePosition
Mr. Srinivas Sadu Executive Chairman
Mr. Wenjie Zhang Non Exe.Non Ind.Director
View More

Gland Pharma FAQs

Gland Pharma शेयर का खरीद मूल्य 1618 है। लाइव प्राइस और तत्काल ट्रेडिंग के लिए, आप अपने चॉइस ट्रेडिंग खाते में लॉगिन कर सकते हैं या चॉइस के साथ मुक्त डीमैट खाता खोल सकते हैं।

Gland Pharma शेयर खरीदने के लिए अपने चॉइस ट्रेडिंग खाते में लॉगिन करें, या चॉइस डीमैट खाता खोल, फिर फंड जोड़ें, कंपनी का नाम खोजें, अपना ऑर्डर टाइप चुनें और ट्रेड प्लेस करें।

Gland Pharma शेयर का प्राइस-टू-अर्निंग्स (पी/ई) रेशियो 31.66 है। आप सापेक्ष मूल्यांकन के लिए इसकी तुलना सेक्टर के औसत से कर सकते हैं।

Gland Pharma शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 2.73 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

Gland Pharma शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 2.65 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

Gland Pharma का मार्केट कैप 26799.28 CR है। यह कंपनी के आकार की श्रेणी और ट्रेडिंग लिक्विडिटी को दर्शाता है।

Gland Pharma शेयर का 52 सप्ताह का उच्चतम और न्यूनतम मूल्य 2131.00 और 1277.80 है। ये मूल्य मूल्य सीमाएं, ट्रेडिंग रेंज, अस्थिरता, संभावित सपोर्ट/रेजिस्टेंस और मूल्य गति को दर्शाते हैं।

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost